Skip to main content
. Author manuscript; available in PMC: 2021 Jun 26.
Published in final edited form as: Mod Pathol. 2020 Jul 1;33(11):2221–2232. doi: 10.1038/s41379-020-0606-0

Figure 2.

Figure 2.

Site of 156 triple-negative breast carcinoma samples tested with PD-L1 (SP142) immunohistochemistry by PD-L1 result. There is significant association with positive PD-L1 status and primary tumor samples, compared to recurrent and metastatic tumor samples (P = .002, by χ2 test).